World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
24826
World Ranking
14224
National Ranking
73

Klaus Podar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Klaus Podar sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 292 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Klaus Podar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Klaus Podar sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Klaus Podar is affiliated with the Karl Landsteiner University of Health Sciences in Austria. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Molecular Biology, Hematology, and Oncology. This expertise is reflected across numerous publications centered on cancer and blood disorders.

The main topics of their work include:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Ubiquitin and proteasome pathways
  • Bone health and treatments
  • RNA Interference and Gene Delivery

Among their recent papers are the following:

  • Selinexor for the treatment of multiple myeloma, 2020, Expert Opinion on Pharmacotherapy
  • Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond, 2021, Cancers
  • The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology, 2021, Cancers

They also contributed to research published in other venues such as PubMed and Clinical Cancer Research, with papers like BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase (2025) and Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans (2020).

Klaus Podar frequently publishes in journals such as:

  • Cancers
  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Expert Opinion on Pharmacotherapy
  • Leukemia

Their collaborations include multiple co-authors with whom they have published extensively. Frequent co-authors include:

  • Sonia Vallet
  • Judith Lind
  • Martin Pecherstorfer
  • Osman Aksoy
  • Martin Sattler

Best Publications

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

    Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar

  • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

    Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

  • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

    Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch

  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

    Ajai Chari;Dan T Vogl;Maria Gavriatopoulou;Ajay K Nooka

  • Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

    Yu Tzu Tai;Myles Dillon;Weihua Song;Merav Leiba

  • Critical role for Gab2 in transformation by BCR/ABL

    Martin Sattler;M.Golam Mohi;Yuri B Pride;Laura R Quinnan

  • The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

    Klaus Podar;Kenneth C. Anderson

  • Bone marrow microenvironment and the identification of new targets for myeloma therapy.

    K Podar;D Chauhan;K C Anderson

  • Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

    Toshiaki Hayashi;Teru Hideshima;Masaharu Akiyama;Klaus Podar

  • Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

    Teru Hideshima;Hiroshi Ikeda;Dharminder Chauhan;Yutaka Okawa

  • Blockade of Hsp27 Overcomes Bortezomib/Proteasome Inhibitor PS-341 Resistance in Lymphoma Cells

    Dharminder Chauhan;Guilan Li;Reshma Shringarpure;Klaus Podar

  • Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

    Yu-Tzu Tai;Xian-Feng Li;Iris Breitkreutz;Weihua Song

  • Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

    Noopur Raje;Shaji Kumar;Shaji Kumar;Teru Hideshima;Kenji Ishitsuka

  • Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

    Dharminder Chauhan;Ajita V. Singh;Mohan Brahmandam;Ruben Carrasco

  • A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

    Martin Sattler;Yuri B. Pride;Patrick Chi-Chung Ma;Jessica L. Gramlich

  • Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

    Teru Hideshima;Dharminder Chauhan;Klaus Podar;Robert L Schlossman

  • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.

    S Lentzsch;R LeBlanc;K Podar;F Davies

Frequent Co-Authors

Teru Hideshima
Teru Hideshima Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Noopur Raje
Noopur Raje Harvard University
Martin Sattler
Martin Sattler Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Robert L. Schlossman
Robert L. Schlossman Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA can open doors to a wide range of health-related careers. For those interested in getting started quickly, consider an lpn program no entrance exam. These programs offer a streamlined route into nursing by eliminating standardized test requirements, making them ideal for students seeking a fast entry into the workforce.

If your goals include medical management, an degree in healthcare administration builds leadership and organizational skills for health services roles. This is a valuable online option for those interested in running clinics, managing hospital departments, or leading health organizations.

For registered nurses aiming for advanced clinical roles, adn to fnp bridge programs allow professionals to become family nurse practitioners without starting from scratch. These bridge programs are flexible and support career advancement for working nurses.

Those passionate about nutrition and preventive health can pursue an online bs in nutrition. This degree is ideal for future dietitians, wellness specialists, or anyone seeking to promote healthy living through science-backed knowledge.

Best Scientists Citing Klaus Podar

Trending Scientists

Recently Published Articles